β受体阻断剂在婴儿血管瘤中的应用  

Application of β receptor blockers in infantile hemangioma

作　　者：于鲁 李丽[1] 马琳[1] YU Lu;LI Li;MA Lin(Department of Dermatology,Beijing Children's Hospital,Capital Medical University,Beijing 100045,China)

机构地区：[1]首都医科大学附属北京儿童医院皮肤科,北京100045

出　　处：《世界临床药物》2019年第12期821-825,共5页World Clinical Drug

基　　金：首都卫生发展科研专项基金(2016-2093);北京市属医院科研培育计划(PX2016014);北京医院管理局儿科学科协同发展中心专项(XTZD20180502)。

摘　　要：婴儿血管瘤是生长期儿童最常见的肿瘤之一。应用普萘洛尔治疗婴儿血管瘤有效率较高、安全性较好,已成为系统治疗婴儿血管瘤的首选药物。临床上应用β受体阻断剂治疗血管瘤已有较长时间,外用β受体阻断剂也逐渐被证实在血管瘤治疗中具有一定疗效,但其机制、疗程及安全性等仍需进行更多的研究及评估。本文对普萘洛尔及其他类型β受体阻断剂治疗婴儿血管瘤的机制及疗效进行简单综述,旨在为临床上更好地治疗婴儿血管瘤提供理论依据。Infantile hemangioma is one of the most common tumors in the growth period of children.Propranolol has high efficacy and safety in the treatment of infantile hemangioma.It has become the first choice of systemic therapy for infantile hemangioma.It has been a long time sinceβreceptor blockers were used in the treatment of hemangioma.The efficacy of externalβreceptor blockers in the treatment of hemangioma has been gradually confirmed.However,its mechanism,course of treatment and safety still need more research and evaluation.In this paper,the mechanism and efficacy of propranolol and otherβreceptor blockers in the treatment of infantile hemangioma were reviewed in order to provide a theoretical basis for better clinical treatment of infantile hemangioma.

关 键 词：婴儿血管瘤 Β受体阻断剂 系统治疗 

分 类 号：R541.6[医药卫生—心血管疾病] R725.4[医药卫生—内科学]